Use of Nonsteroidal Anti-inflammatory Drugs for COVID-19 Infection: Adjunct Therapy?. Issue 6 (November 2020)

• Record Type: Journal Article
• Authors: Zhao, Daniel; Zhang, Sandy; Igawa, Teryn; Frishman, William
• Is Part Of: Cardiology in review. Volume 28:Issue 6(2020)
• Publication Date: 2020-11
• Subjects: coronavirus -- COVID-19 -- nonsteroidal anti-inflammatory drugs -- adjunct therapy; Cardiology -- Periodicals; 616.12
• DOI: 10.1097/CRD.0000000000000340
• Languages: English
• ISSNs: 1061-5377

Abstract

Abstract : Severe acute respiratory distress syndrome coronavirus 2 (COVID-19) is the cause of the current pandemic, which remains a tremendous cause of morbidity and mortality worldwide. Although there are numerous trials underway, there is currently no medication known to cure the infection. Nonsteroidal anti-inflammatory drugs (NSAIDs) are inexpensive, widely available medications with antiviral and anti-inflammatory properties and may have utility as an adjunct therapy to improve outcomes in patients with severe COVID-19 infection. A thorough PubMed literature review on the therapeutic use of NSAID was conducted to provide a comprehensive perspective of the role of NSAIDs in treating COVID-19. NSAIDs may be a useful adjunct therapy for patients with severe COVID-19 infection, but further investigation and clinical trials are necessary to ensure their safety and efficacy.